Breast cancer drug developed by UB professor moves closer to clinical trials

Published October 24, 2017 This content is archived.

Print

WBFO-FM reports on For-Robin, a UB startup company that is showing strong progress in developing a new and effective cancer treatment that it hopes to begin testing in humans. In the story, Kate Rittenhouse-Olson, professor emeritus of biotechnical and clinical laboratory sciences and the founder for For-Robin, said, “We want to give each person the time to fulfill their promise, I think. So if we could help the young women with this triple-negative form fight their cancer, add one more thing to help them fight their cancer, it would be great."

Read more:

http://news.wbfo.org/post/buffalo-based-start-fighting-cancer-personal

https://www.bizjournals.com/buffalo/news/2017/10/04/for-robin-seeking-investors-ready-for-human-trials.html

http://news.wbfo.org/post/buffalo-based-start-fighting-cancer-personal

http://www.wben.com/articles/wben-buffalo-business-report-thursday-october-19th-2017 

https://www.dddmag.com/news/2017/10/ub-spinoff-company-moves-one-step-closer-human-clinical-trials

https://medicalxpress.com/news/2017-10-ub-spinoff-company-for-robin-closer.html

Media Contact Information

Media Relations (University Communications)
330 Crofts Hall (North Campus)
Buffalo, NY 14260-7015
Tel: 716-645-6969
ub-news@buffalo.edu